A phase 1b–2 trial published in The New England Journal of Medicine evaluated the combination of two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed or refractory multiple...
New clinical guidance outlines the use of blood-based biomarker tests for Alzheimer’s diagnosis in patients with cognitive impairment, aiming to support more consistent and evidence-based application in...
A phase 3 trial confirms that combining ibrutinib with venetoclax yields superior measurable residual disease clearance, progression-free survival, and overall survival in patients with chronic lymphocytic...
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
Acalabrutinib demonstrated a significantly safer cardiovascular profile and lower mortality risk compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia based on a large retrospective...
Anticoagulation after trauma reduces the risk of stroke and transient ischemic attacks without significantly increasing bleeding or readmissions, according to the results of a study presented at the Society...
This phase 3 study demonstrated that roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is noninferior to rHuEPO-α in improving hemoglobin levels for chemotherapy-induced anemia,...
Researchers developed a cross-sectional survey to understand the public and provider awareness of postmenopausal bleeding as a symptom of endometrial cancer.
A recent phase 3 study found that venetoclax-obinutuzumab improves progression-free survival and quality of life compared with chlorambucil-obinutuzumab in patients with untreated chronic lymphocytic...
